RxDoctor Payments DataLook up a doctor →

Elshaday Teferi, NP

Psychiatric/Mental Health · Columbia, MDNPI 1689215527

Payments from drug & device makers

$10,997in general payments, 2019–2025

Across 567 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$949
  • Axsome Therapeutics, Inc.$899
  • Alkermes, Inc.$837
  • Neurocrine Biosciences, Inc.$799
  • plus $5K from 22 others

What the payments were for

  • Food & beverage$10,997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,997 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$51,137
Medicare patients
115
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atomoxetine Hcl25$3,296
Bupropion XlBupropion Hcl45$1,733
Aripiprazole55$1,119
Escitalopram Oxalate88$1,031
Duloxetine Hcl21$908
Lamotrigine49$855
Mirtazapine33$816
Olanzapine35$766
Sertraline Hcl51$730
Fluoxetine Hcl28$567
Quetiapine Fumarate40$506
Divalproex Sodium26$443
Risperidone29$406
Trazodone Hcl38$357
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$211$73051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →